Professor Eric Deutsch

Professor Éric Deutsch is a radiation oncologist at the Gustave Roussy Institute, where he has headed the Department of Radiation Oncology since 2012. He is also a Full Professor and Hospital Practitioner (PU-PH) in Radiation Oncology at Paris-Saclay University. Since 2022, he has served as Vice Dean for Research at the Faculty of Medicine at Paris-Saclay.

A recognized specialist in radiotherapy, Professor Deutsch focuses his work on optimizing cancer treatments, particularly through the integration of innovative technologies such as artificial intelligence (AI), radiomics, and radiobiology. He is the lead investigator of the RHU LySAIRI project (Lymphocyte-Sparing Artificial Intelligence-guided Radio-Immunotherapy), a €9.9 million initiative aimed at developing AI-guided radio-immunotherapy strategies while preserving lymphocytes (PubMed).

As Director of the joint research unit INSERM U1030 “Molecular Radiotherapy and Therapeutic Innovations,” he oversees preclinical research in radiobiology, immunotherapy, biomarkers, and radiomics applied to radiotherapy. His work seeks to better understand interactions between tumors and their microenvironment in order to personalize and enhance treatment efficacy.

Professor Deutsch is also the organizer of the international ImmunoRad conference, which brings together global experts to discuss advances in radiotherapy-immunotherapy combinations. The 9th edition of the conference, held in Paris in September 2025, highlighted recent innovations in this field, including immunomodulatory radiotherapy and lymph node preservation strategies (PubMed).

Among his recent publications:

• Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Deutsch E. Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results. Signal Transduction and Targeted Therapy. March 2025.
• Chen J, Levy A, Tian A-L, Deutsch E. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell. March 2025.
• Levy A, Deutsch E, Le Péchoux C. Local Immunoradiotherapy in Patients With Metastatic Soft-Tissue Sarcoma. JAMA Oncology. 2024.
• Sun R, Emeriau Y, Achkar S, Mitrea D, Laville A, Deny N, Bockel S, Deutsch E. CD8 radiomics signature to assess inter-lesion spatial heterogeneity and cold liver lesions in advanced non-small cell lung cancers treated with durvalumab. Journal of Clinical Oncology. 2024; 42(16_suppl):2511-2511.

Through his research and dedication to teaching, Professor Éric Deutsch plays a key role in the development of new therapeutic strategies against cancer, combining technological innovation with a patient-centered approach.